Athira Pharma, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Athira Pharma shifts its focus to ATH-1105 for ALS treatment after Phase 2/3 trial results for fosgonimeton in Alzheimer's disease fall short of statistical significance.
Athira Pharma's 10-K filing outlines the company's stock structure, voting rights, and compliance with securities regulations, while also detailing ongoing clinical trials and risk factors.